Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Sorafenib use in the transplant setting.

Castelli G, Burra P, Giacomin A, Vitale A, Senzolo M, Cillo U, Farinati F.

Liver Transpl. 2014 Sep;20(9):1021-8. doi: 10.1002/lt.23911. Epub 2014 Aug 4. Review.

2.

Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.

Jia N, Liou I, Halldorson J, Carithers R, Perkins J, Reyes J, Yeh M, Stohr E, Rao S, Lin EH.

Anticancer Res. 2013 Jun;33(6):2797-800.

PMID:
23749944
3.

Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.

Sotiropoulos GC, Nowak KW, Fouzas I, Vernadakis S, Kykalos S, Klein CG, Paul A.

Transplant Proc. 2012 Nov;44(9):2754-6. doi: 10.1016/j.transproceed.2012.09.022.

PMID:
23146514
4.

Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.

Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Review.

PMID:
23044808
5.

Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

De Simone P, Crocetti L, Pezzati D, Bargellini I, Ghinolfi D, Carrai P, Leonardi G, Della Pina C, Cioni D, Pollina L, Campani D, Bartolozzi C, Lencioni R, Filipponi F.

Transplant Proc. 2014 Jan-Feb;46(1):241-4. doi: 10.1016/j.transproceed.2013.10.035.

PMID:
24507059
6.

Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.

Golse N, Radenne S, Rode A, Ducerf C, Mabrut JY, Merle P.

Exp Clin Transplant. 2018 Apr;16(2):227-236. doi: 10.6002/ect.2015.0299. Epub 2016 May 17. Review.

7.

Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.

Chen K, Man K, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q.

Liver Transpl. 2014 Mar;20(3):261-9. doi: 10.1002/lt.23806. Epub 2014 Jan 27. Review.

8.

Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

de'Angelis N, Landi F, Carra MC, Azoulay D.

World J Gastroenterol. 2015 Oct 21;21(39):11185-98. doi: 10.3748/wjg.v21.i39.11185. Review.

9.

Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.

Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J.

World J Gastroenterol. 2014 Nov 21;20(43):16275-81. doi: 10.3748/wjg.v20.i43.16275.

10.

Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.

Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Narayanan Menon KV, Estfan B, Romero-Marrero C, Aucejo F.

Clin Transplant. 2013 Jul-Aug;27(4):555-61. doi: 10.1111/ctr.12150. Epub 2013 Jun 13.

PMID:
23758296
11.

Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.

Antoniou EA, Margonis GA, Amini N, Anastasiou M, Angelou A, Kim Y, Kouraklis G.

J BUON. 2016 Sept-Oct;21(5):1189-1194.

PMID:
27837622
12.

[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].

Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Okusaka T.

Nihon Shokakibyo Gakkai Zasshi. 2012 Aug;109(8):1346-54. Review. Japanese. No abstract available.

PMID:
22863957
13.

Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.

Gadaleta-Caldarola G, Divella R, Mazzocca A, Infusino S, Ferraro E, Filippelli G, Daniele A, Sabbà C, Abbate I, Brandi M.

Future Oncol. 2015;11(16):2263-6. doi: 10.2217/fon.15.161. No abstract available.

PMID:
26260805
14.

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.

Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi G, Bhoori S, Mazzaferro V.

J Hepatol. 2013 Jul;59(1):59-66. doi: 10.1016/j.jhep.2013.02.026. Epub 2013 Mar 14.

PMID:
23500153
15.

Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?

Fujiki M, Aucejo F, Kim R.

Clin Transplant. 2013 Mar-Apr;27(2):169-77. doi: 10.1111/ctr.12042. Epub 2012 Dec 6. Review.

PMID:
23216662
16.

Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.

Poullenot F, Bioulac-Sage P, Laumonier H, Saric J, Carteret T, Blanc JF.

Acta Oncol. 2014 Mar;53(3):420-3. doi: 10.3109/0284186X.2013.795286. Epub 2013 May 29. No abstract available.

PMID:
23713857
17.

Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.

Naqi N, Ahmad S, Murad S, Khattak J.

Hematol Oncol Stem Cell Ther. 2014 Mar;7(1):27-31. doi: 10.1016/j.hemonc.2013.11.003. Epub 2013 Dec 12.

18.

Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.

Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P.

World J Gastroenterol. 2016 Jun 21;22(23):5384-92. doi: 10.3748/wjg.v22.i23.5384.

19.

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Faivre S, de Gramont A, Raymond E.

Target Oncol. 2016 Aug;11(4):565-7. doi: 10.1007/s11523-016-0427-8. No abstract available.

PMID:
26996978
20.

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

Hollebecque A, Malka D, Ferté C, Ducreux M, Boige V.

Eur J Cancer. 2015 Feb;51(3):327-39. doi: 10.1016/j.ejca.2014.12.005. Epub 2015 Jan 2. Review.

PMID:
25559615

Supplemental Content

Support Center